Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Business Insider16h
Intra-Cellular Announces Positive Data For Caplyta As Maintenance Treatment For Schizophrenia
The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day. The biopharmaceutical company found that the time to relapse ...
GlobalData on MSN1d
Teva’s long-lasting schizophrenia injectable shines in Phase III
Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...
Teva Presents New Research On Schizophrenia, Highlighting SOLARIS Trial Results For TEV-749
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new, positive data on social ...
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...